Sellas Life Sciences Group Inc

SLS is in a Stage 4 decline, with a decisive support failure confirming a lower-high/lower-low sequence. The medium-term bias is bearish, backed by breakdown below key support. In the short term, price remains below the downward-sloping 9 EMA and 21 EMA, which are acting as resistance, making Sell Now into EMA rejections the appropriate execution alignment.

• ↑78/80 deaths collected in REGAL Phase 3 trial, readout imminent.
• ↑$107.1M cash reserves support GPS development and strategic priorities.
• ↓24.5× price-to-book signals stretched valuation amid biotech volatility.